HUMACYTE
Humacyte develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, which are formed in vitro from banked vascular smooth muscle cells and then decellularized to eliminate the risk of rejection; and vascular grafts.
HUMACYTE
Industry:
Biotechnology Medical Medical Device
Founded:
2004-01-01
Address:
Morrisville, North Carolina, United States
Country:
United States
Website Url:
http://www.humacyte.com
Total Employee:
101+
Status:
Active
Contact:
9193139634
Total Funding:
692.86 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics Global Site Tag
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Fresenius Medical Care
Fresenius Medical Care investment in Post-IPO Equity - Humacyte
OrbiMed
OrbiMed investment in Post-IPO Equity - Humacyte
Alexandria Venture Investments
Alexandria Venture Investments investment in Post-IPO Equity - Humacyte
Morgan Creek Capital Management
Morgan Creek Capital Management investment in Post-IPO Equity - Humacyte
UBS O'Connor
UBS O'Connor investment in Post-IPO Equity - Humacyte
Monashee Investment Management
Monashee Investment Management investment in Post-IPO Equity - Humacyte
Silicon Valley Bank
Silicon Valley Bank investment in Debt Financing - Humacyte
Fresenius Medical Care
Fresenius Medical Care investment in Corporate Round - Humacyte
California Institute for Regenerative Medicine
California Institute for Regenerative Medicine investment in Grant - Humacyte
California Institute for Regenerative Medicine
California Institute for Regenerative Medicine investment in Venture Round - Humacyte
Key Employee Changes
Official Site Inspections
http://www.humacyte.com Semrush global rank: 4.77 M Semrush visits lastest month: 1.94 K
- Host name: ec2-67-202-46-212.compute-1.amazonaws.com
- IP address: 67.202.46.212
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Humacyte"
Leadership - Humacyte Global, Inc.
Jul 23, 2024 Dr. Niklason is the founder of Humacyte and has served as its President and CEO since 2020. She served Humacyte as a senior scientist from 2004 through 2020. ... Mr. …See details»
Our Story - Humacyte Global, Inc.
Jul 23, 2024 Our commitment to disruptive, meaningful innovation goes beyond mere advancement. It’s a dedication to setting new standards that challenge the status quo and …See details»
Humacyte - The Org
Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients …See details»
Humacyte - Crunchbase Company Profile & Funding
Humacyte develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, …See details»
Humacyte, Inc. (HUMA) Company Profile & Facts - Yahoo Finance
See the company profile for Humacyte, Inc. (HUMA) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives …See details»
Humacyte, Inc. - AnnualReports.com
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the …See details»
Humacyte, Inc.
Humacyte, Inc. (Exact name of registrant as specified in its charter) _____ D e l aw are 85-1763759 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer …See details»
Investor Relations | Humacyte, Inc.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ …See details»
Humacyte Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Humacyte is a regenerative medical technology company focused on the development of human acellular matrix products for vascular and non-vascular applications. It …See details»
Humacyte, JDRF Collaborating to Develop Insulin-Producing …
Apr 27, 2023 NEW YORK, N.Y. and DURHAM, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HU MA), a biotechnology company pioneering the development and …See details»
Careers - Humacyte Global, Inc.
Humacyte is aware that some job seekers are receiving fake employment offers and requests for personal and banking information from individuals or organizations posing as Humacyte. If you …See details»
The Matrix Recellularized: Humacyte Manufactures Bioengineered …
Apr 4, 2022 Humacyte Founder, President, and CEO Laura Niklason, MD, PhD. There is a global shortage of transplantable organs, from which have emerged two main approaches to …See details»
Humacyte - Overview, News & Similar companies | ZoomInfo.com
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024 DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: …See details»
Lab-Grown Blood Vessels Could Help Dialysis Patients
Mar 11, 2020 The company Humacyte is developing bioengineered blood vessels that become incorporated into a patient’s blood vessels. Because the body regenerates the implanted …See details»
Working At Humacyte: Company Overview and Culture - Zippia
Mar 14, 2024 Humacyte, Inc. develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and …See details»
Investors - Humacyte Global, Inc.
© 2024 Humacyte Global, Inc. All Rights Reserved. US-DIS-000136. You are now leaving humacyte.com. ProceedSee details»
Humacyte: FDA Waiting Game Bleeding Company Dry
2 days ago Humacyte’s ATEV achieved a 30-day secondary patency rate after 30 days of 90.2%, a conduit infection rate of 2.0%, and an amputation rate of 9.8% versus 78.9% …See details»
Humacyte’s (HUMA) Statements to Investors Called Into
4 hours ago Humacyte, Inc. (HUMA) Securities Class Action: The lawsuit claims that Humacyte and certain of its executives failed to disclose material adverse facts about the company’s …See details»
Alpha Healthcare and Humacyte Announce Nominees for Election …
Aug 13, 2021 Nominees bring depth and diversity of scientific, commercial and financial experience to Board; NEW YORK and DURHAM, N.C., Aug. 13, 2021 (GLOBE NEWSWIRE) - …See details»
HUMA Investors Have Opportunity to Lead Humacyte, Inc.
3 days ago NEW YORK, Dec. 13, 2024 /PRNewswire/ --. Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) …See details»